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Summary
INTRODUCTION: “Behavioural and psychological symp-
toms of dementia” (BPSD) refers to a heterogeneous
group of clinical manifestations related to dementia, in-
cluding apathy, depression, anxiety, delusions, hallucina-
tions, sexual or social disinhibition, sleep-wake cycle dis-
turbances, aggression, agitation and other behaviours
considered inappropriate. Because of the complexity and
heterogeneity of BPSD, as well as the fragility and mul-
timorbidity of the elderly, pharmacological treatment ap-
pears to be limited in terms of safety and efficacy, and non-
pharmacological therapies are today considered the first
choice. There is growing evidence that interventional ap-
proaches such as electroconvulsive therapy (ECT), repeti-
tive transcranial magnetic stimulation (rTMS), transcranial
direct current stimulation (tDCS), deep brain stimulation
(DBS), and vagus nerve stimulation (VNS) could be safe
and efficient options for several psychiatric illnesses in a
population presenting resistance to and/or intolerance of
pharmacotherapy.
AIMS: The aim of the present work is to provide a qualita-
tive review of the state of the art in interventional psychia-
try in the treatment of BPSD. A particular focus will be on
depression and agitation, which represent major stressors
on caregivers and a primary cause of institutionalisation.
CONCLUSIONS: ECT is probably the most promising in-
terventional procedure needing further investigation in or-
der to obtain specific protocols and a consensus on in-
dications. Preliminary data on rTMS, tDCS, and VNS are
encouraging although randomised controlled trials to in-
vestigate and compare their efficacy in the treatment of
BPSD are still lacking. Their feasibility profile could rep-
resent an important advantage over ECT. DBS could rep-
resent a very effective therapy for behavioural disorders,
but knowledge of the precise neuroanatomical targets for
BPSD is currently too limited to justify this invasive ap-
proach.
Keywords: BPSD, interventional psychiatry, dementia,
ECT, rTMS, DBS, tDCS, VNS
Introduction
Behavioural and psychological symptoms of dementia
(BPSD) are a heterogeneous group of clinical manifes-
tations related to dementia, including apathy, depression,
anxiety, delusions, hallucinations, sexual or social disin-
hibition, sleep-wake cycle disturbances, aggression, agita-
tion and other behaviours considered inappropriate [1, 2].
BPSD are experienced by 50% (point prevalence) to 90%
(long-term prevalence) of patients diagnosed with demen-
tia [3, 4]. They have a negative impact on cognitive decline
[5] and increase secondary complications [6].
The management of BPSD is complex as their aetiopatho-
genesis is multifactorial and includes biological factors
(e.g., brain lesions, changes in neuromodulation, comor-
bidities, pain, personality traits) and nonbiological factors
(e.g., and environmental stressors) [2].
Because of the complexity and heterogeneity of BPSD,
as well as the fragility and multimorbidity of the elderly
population, in whom dementia has the highest prevalence,
pharmacological treatment appears to be limited in terms
of safety and efficacy, and nonpharmacological therapies
are considered today the first choice [7].
Currently, there is growing evidence that interventional
approaches such as electroconvulsive therapy (ECT) [4],
repetitive transcranial magnetic stimulation (rTMS) [8, 9],
transcranial direct current stimulation (tDCS) [10], deep
brain stimulation (DBS) [11, 12], and vagus nerve stimula-
tion (VNS) [13, 14] could be reasonably safe and efficient
options for the treatment of several psychiatric illnesses in
a population presenting resistance to and/or intolerance of
pharmacotherapy.
The rationale for the application of these techniques in the
treatment of BPSD is the hypothesis of disrupted neuro-
modulation, involving dopaminergic, noradrenergic, glu-
tamatergic, GABAergic and serotoninergic pathways [2],
which may be targets for the neuromodulation techniques
mentioned above. Below, we discuss the specific targets of
each interventional approach.
The aim of the present work is to provide a review of the
state of the art in interventional psychiatry in the treatment
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represent major stressors on caregivers, a primary cause of
institutionalisation and increase of the costs of therapy i.e.,
depression and agitation [15].
Electroconvulsive therapy
ECT consists of providing an electrical current through the
brain that induces a short generalised seizure considered
to be the therapeutic element. This procedure is consid-
ered today the most efficacious antidepressant treatment
for acute severe major depression. It is indicated – in as-
sociation or not with pharmacotherapy – for depression,
bipolar disorder (for both manic and depressive phases),
treatment-resistant schizophrenia [16], catatonia in various
disorders [17, 18] and behavioural changes in other mental
disorders such as autism [19]. Suicidal ideation is rapidly
relieved by ECT, with a complete resolution in up to 81%
of patients after 2 weeks of treatment [20]. ECT has also
been successfully employed as a treatment for refractory
status epilepticus after exhausting pharmacotherapy
[21–23].
The precise mechanisms of action are unknown, and dif-
ferent models have been proposed. One finding is a signif-
icant increase in cerebral gamma-aminobutyric acid (GA-
BA) concentration after ECT [24]. This could be a
rationale for its application in dementia-related apathy and
depression, as a significant GABA decrease in the frontal
and temporal cortex and high GABA plasma concentra-
tions were found in patients affected by Alzheimer’s dis-
ease presenting with these syndromes [25]. On the basis of
other hypotheses, studies on haemodynamic changes after
ECT have shown an increased blood flow in the thalamus
as well as changes in blood flow in the anterior cingulate
and medial frontal cortex and thalamus [26]. Moreover,
positron emission tomography showed a decrease in cere-
bral metabolism in prefrontal and parietal areas, and a
positive correlation with improvement in depression [27].
Other researchers pointed out the increased levels of brain-
derived neurotrophic factor (BDNF) and the normalisation
of the hypothalamic-pituitary-adrenal axis [28]. Several
studies have found a higher remission in elderly patients
treated with ECT than in younger patients [29–32]. The
idea that this observation can be explained by different
psychopathological profiles of the two populations is not
clearly supported by current evidence [33].
The potential role of ECT in the treatment of BPSD may be
among its most intriguing fields of investigation, with in-
creasing interest in the literature during the last decade [4].
However, the lack of sufficiently large randomised con-
trolled studies prevents a large consensus as to a clear rec-
ommendation for the indication of ECT in the treatment of
one or more BPSD.
Seven case reports have recently shown the safety and effi-
cacy of ECT in the treatment of agitation [34–37], aggres-
sion [36, 38], treatment-resistant depression [39] and vo-
cally disruptive behaviour (pathological yelling) [40]. Both
a cohort study [41] and a naturalistic prospective study
[42] support these observations. Treatment of apathy and
hallucinations has not been investigated in specifically de-
signed trials focusing on patients suffering from dementia,
but the efficacy of this technique in the treatment of posi-
tive and negative symptoms of psychosis [43] represents a
sufficient rationale to investigate this domain. ECT proved
to be rapidly effective and well tolerated, with occasion-
al side effects such as atrial fibrillation needing cardiover-
sion, mild decreased cognition, confusion, increased som-
nolence, urinary retention, headache and mild increases in
serum amylase. It is important, however, to observe that
ECT may improve cognition with specific electrode posi-
tioning and treatment parameters [33, 44].
A recent review [45] emphasised that ECT is a key treat-
ment option in late life depression and that the level of ad-
verse events does not increase after ECT for subjects in any
age group, and concluded that ECT is as effective and safe
for older depressed patients as it is for younger ones.
Although there is no general consensus about the protocol
that should be adopted in the treatment of BPSD, a recent
review and case report suggests that an alternation of acute
and maintenance administration of treatment could prevent
relapses over time [4].
Repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation is a neuro-
modulatory technique based on the electromagnetic induc-
tion of an electric field in the brain [46]. With sufficient
magnitude and density to depolarise neurones, repeated
stimulation can modulate cortical excitability, with a
durable inhibitory or excitatory effect, even after the stim-
ulation [47].
Treatment resistant major depressive disorder is the main
indication of rTMS in psychiatry, endorsed by the clinical
practice guidelines for mood disorders [48].
A systematic review and meta-analysis [49] concludes that
rTMS produces a significant decrease of symptoms in non-
psychotic depression in comparison with sham treatment
with, however, a moderate strength of evidence for remis-
sion and a lack of data concerning the persistence of ben-
efits over time. As the treatment has proven to be safe and
well tolerated, it is regarded as a reasonable option in the
case of failure of two pharmacological treatments.
A recent state-of-the-art review on the use of rTMS for de-
pression pointed out that comparisons of rTMS and ECT
showed better effectiveness of ECT with minor costs.
However, it also showed that rTMS had higher patient
preference and fewer side effects than ECT [50].
The recommendations given by the Clinical TMS Society
[51], based on its review of available rTMS research in de-
pression, support an indication for adults with refractory
major depressive disorders, or acute symptom relief for
partial responders or those who have a history of delayed
response to medication in past episodes. As the greatest ef-
ficacy in the treatment of depressive symptoms with rTMS
was obtained using excitatory stimulation of the left dorso-
lateral prefrontal cortex [52], this may be a target for the
treatment of affective BPSD.
A recent randomised, double-blind, sham-controlled study
[53] investigated, in a sample of 26 patients suffering from
an Alzheimer disease, the efficacy of an excitatory stimu-
lation of the left dorsolateral prefrontal cortex as adjunc-
tive therapy for the treatment of affective BPSD. Despite
the study’s limitations due to the size of the sample, a sig-
nificant improvement in both cognitive functions and af-
fective BPSD was found in the group receiving both rTMS
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and low-dose antipsychotic medication in comparison with
the group receiving sham rTMS.
Hallucinations could be another interesting field of inves-
tigation for a potential role of rTMS. Indeed, several stud-
ies have shown transient hyperactivity of specific brain
areas in temporal, frontal and parietal lobes in patients ex-
periencing hallucinatory symptoms [54]. The hypothesis
that inhibitory rTMS, targeting the primary auditory cor-
tex, could be an effective treatment for drug-resistant hal-
lucinations is supported by preliminary evidence [55]. This
could provide a rationale for the application of inhibitory
rTMS in the treatment of visual BPSD.
Another recent work [56] investigated the possible role of
rTMS in the treatment of apathy in nine patients suffering
from mild cognitive impairment. Results were encouraging
as apathy improved, suggesting a possible role of rTMS at
multiple levels for the treatment of BPSD.
The most common side effect of rTMS is local discomfort
or pain, which is usually mild and responds to simple anal-
gesia. The risk of seizures, affective switch and psychosis
is very low. Hearing impairment can be prevented by using
hearing protection. Clinical evidence suggests that rTMS
has no adverse impact on cognition [48].
Transcranial direct current stimulation
Transcranial direct current stimulation provides an electri-
cal stimulation to the brain via two surface sponge elec-
trodes attached to distinct areas of the scalp with a rubber
headband [57]. This procedure presents several practical
advantages over alternative neuromodulation modalities as
it has a favourable safety-feasibility profile, offers a con-
vincing placebo for studies, and is both portable and inex-
pensive [10].
The mechanism of action of tDCS is still under investiga-
tion. A multimodal influence on the central nervous system
could be linked to its ability to modify neuronal membrane
polarity and, by so doing, its threshold for action potential
generation. tDCS could also play a positive role in cell mi-
gration (electrotaxis), orientation, differentiation and me-
tabolism, as well as inflammation, neurogenesis, neuro-
plasticity and angiogenesis [58].
A recent systematic review showed the state of the art in
the applications of tDCS in psychiatry through analysis of
125 articles [10]. A protocol of 10 tDCS administrations
twice a day improved depressive symptoms in patients suf-
fering from treatment-resistant major depressive disorder
[59]. The combination with pharmacological treatment is
generally considered superior to tDCS monotherapy [10].
However, the efficacy of this technique for resistant de-
pression is controversial, as some studies show that tDCS
is not superior to antidepressants [60, 61] or even placebo
[62]. Methodological issues, in particular under-powered
study designs, may go some way explaining these incon-
sistencies.
Efficacy of tDCS on hallucinations in patients suffering
from refractory schizophrenia has also been shown [63].
Side effects are generally mild and transient and include
itching, tingling and headache, and suggest that tDCS is a
safe procedure [64].
There is a lack of studies focusing on its efficacy in the
treatment of BPSD, but it has been shown that it may con-
tribute to cognitive improvement in patients suffering from
brain injury [65, 66].
Because of the safety-feasibility profile of this technique
and the preliminary data suggesting its efficacy in refrac-
tory psychiatric illnesses, studies focusing on its possible
role in the treatment of BPSD could offer a basis for a valid
therapeutic option and clearly prompts further studies.
Deep brain stimulation
DBS is an invasive procedure consisting of implanting
one or more electrode arrays into a specific region of the
brain using neuroimaging-guided stereotactic techniques
[11]. Today the complex action of DBS is reasonably well
understood and is conceived as a multimodal modulation
of neuronal activity, strictly depending on its localisation
and intensity [11].
Efficacy of DBS in refractory depression and obsessive-
compulsive disorder has been documented [12], although
the current state of evidence for the treatment of depression
is contested with a study finding non-superiority over
placebo of this technique [67].
Only one phase I trial investigated the possible benefits
of DBS in Alzheimer’s disease, focusing on memory by
targeting the vertical portion of the fornix within the hy-
pothalamus [68]. Researchers suggested possible improve-
ments and/or slowing in the rate of cognitive decline at 6
and 12 months in some patients, with no serious adverse
events. Considering the small size of the sample (six pa-
tients), further investigation is needed in order to compare
the effectiveness of this invasive procedure with other
treatment options.
The design of prospective studies focusing on DBS as a
treatment of specific BPSD needs a better understanding of
its complex aetiopathogenesis and neuroanatomical under-
pinnings, in order to allow sufficiently precise targeting of
stimulation to justify the exposure to the risks of a neuro-
surgical intervention.
Vagus nerve stimulation
VNS is a therapy for treatment-resistant depression, which
has been recently approved by the US Food and Drugs Ad-
ministration. It can provide significant antidepressant ef-
fects [69], though the underlying mechanisms have not yet
been completely clarified [70]. The vagus nerve can be
stimulated in two ways: an invasive technique (iVNS) re-
quiring the surgical implantation of a subcutaneous small
pulse generator in the left thoracic region and a non-in-
vasive transcutaneous technique (tVNS), obtained through
the application of the stimulator to the auricular concha via
ear clips [71].
Both iVNS and tVNS have shown a significant albeit lim-
ited improvement in depressive symptoms in several trials
[71]. Mood improvement was detectable after 10 weeks
[72], with a number needed to treat progressively decreas-
ing over time at 24, 48 and 96 weeks. VNS proved to be
superior to standard treatments in producing a sustained re-
sponse after 48 weeks of administration [73].
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Two studies were designed to explore the efficacy and
safety of VNS in Alzheimer’s disease [74, 75]. Both de-
scribed an improvement of Mini Mental State Examination
and Alzheimer’s Disease Assessment Scale–Cognitive
Subscale scores with a good profile of safety.
These preliminary data concerning the safety and the fea-
sibility of this technique are encouraging and suggest the
possible application of this procedure in the management
of BPSD. However, to the best of our knowledge, no study
has ever tried to assess VNS for BPSD.
Conclusions
The pharmaceutical options for the treatment of BPSD are
limited owing to the safety profile of the drugs approved
for the elderly population, as well as to the limited clinical
improvement obtained with the nonpharmacological inter-
ventions that are currently approved.
In our short review, we investigated the potential role of in-
terventional techniques, considering the possible overlap-
ping role of specific neurocircuits underlying both BPSD
and related symptoms and signs in other psychiatric syn-
dromes.
ECT is probably the most promising interventional pro-
cedure, with preliminary evidence of efficacy in depres-
sion, apathy, aggression, hallucinations and vocally dis-
ruptive behaviour, offering a convincing rationale for the
investigation of specifically designed trials focusing on
the treatment of BPSD. rTMS offers the possibility of
focal neuromodulation, with a safe tolerability profile and
the perspective of allowing better treatment of BPSD and
helping understand better the neurobiological mechanisms
underlying these heterogeneous manifestations. For tDCS
and VNS, data are still very preliminary and controversial
though there are encouraging findings regarding the treat-
ment of depressive symptoms. There is a need for ran-
domised controlled trials in order to investigate and com-
pare their efficacy in the treatment of BPSD. Their
feasibility profile would represent an advantage over other
techniques. DBS may represent a very effective therapy for
specific BPSD, but current knowledge concerning precise
neuroanatomical targeting is too limited to justify an inva-
sive approach.
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